Renin-angiotensin system (RAS) blockers, such as angiotensin converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs), in the context of a multifactorial risk minimization strategy have been tested for their ability to revert CKD progression or at least prevent its further deterioration and were included in guidelines as a standard therapy for diabetic patients with CKD [8–12]. The gene discussed is REN; the disease is chronic kidney disease.